{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:58:12Z","timestamp":1776243492175,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MGC Pharmaceuticals Ltd., Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma is a malignant neoplasm that originates from melanocytes. It continues to pose a significant challenge in oncology due to its aggressive nature and limited treatment options. This study investigates the potential additive effects of PHEC-66, a cannabis extract, in combination with conventional chemotherapeutic agents auranofin, docetaxel, and cisplatin on the viability of a range of melanoma cell lines. These combinations were evaluated using the MTT assay on MM418-C1, MM329, C32, and D24 melanoma cells. There was a nuanced response observed when PHEC-66 was combined with docetaxel and auranofin in these cells, suggesting a potential additive effect. Contrastingly, the combination of PHEC-66 with cisplatin elicited an antagonistic effect, wherein the expected cytotoxicity of this drug was compromised. This unexpected interaction may stem from complex interplays between the agents that influence drug uptake, DNA damage response, and cell survival pathways. These findings underscore the importance of careful selection and assessment of drug combinations, as an additive effect and antagonistic interactions can significantly impact therapeutic outcomes. Further studies are warranted to elucidate the molecular mechanisms behind these interactions and to validate these observations using in vivo models.<\/jats:p>","DOI":"10.3390\/ijms27041794","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:09:19Z","timestamp":1770973759000},"page":"1794","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells"],"prefix":"10.3390","volume":"27","author":[{"given":"Ava","family":"Bachari","sequence":"first","affiliation":[{"name":"The Pangenomics Laboratory, School of Science, RMIT University, Bundoora, VIC 3083, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-4300","authenticated-orcid":false,"given":"Srinivasareddy","family":"Telukutla","sequence":"additional","affiliation":[{"name":"The Pangenomics Laboratory, School of Science, RMIT University, Bundoora, VIC 3083, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazim","family":"Nassar","sequence":"additional","affiliation":[{"name":"The Pangenomics Laboratory, School of Science, RMIT University, Bundoora, VIC 3083, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0343-1781","authenticated-orcid":false,"given":"Terrence","family":"Piva","sequence":"additional","affiliation":[{"name":"School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-035X","authenticated-orcid":false,"given":"Nitin","family":"Mantri","sequence":"additional","affiliation":[{"name":"The Pangenomics Laboratory, School of Science, RMIT University, Bundoora, VIC 3083, Australia"},{"name":"The UWA Institute of Agriculture, The University of Western Australia, Perth, WA 6009, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gieniusz, E., Skrzydlewska, E., and Luczaj, W. (2024). Current Insights into the Role of UV Radiation-Induced Oxidative Stress in Melanoma Pathogenesis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111651"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., and Barsouk, A. (2021). Epidemiology of Melanoma. Med. Sci., 9.","DOI":"10.3390\/medsci9040063"},{"key":"ref_4","first-page":"212242","article-title":"Metastatic melanoma\u2014A review of current and future drugs","volume":"2012","author":"Velho","year":"2012","journal-title":"Drugs Context"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chan, X.Y., Singh, A., Osman, N., and Piva, T.J. (2017). Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071527"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Talloa, D., Triarico, S., Agresti, P., Mastrangelo, S., Attina, G., Romano, A., Maurizi, P., and Ruggiero, A. (2022). BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors. Cancers, 14.","DOI":"10.3390\/cancers14174264"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., and Maddalena, P. (2020). BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers, 12.","DOI":"10.3390\/cancers12071823"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2008.177","article-title":"From UVs to metastases: Modeling melanoma initiation and progression in the mouse","volume":"128","author":"Zaidi","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kim, H.J., and Kim, Y.H. (2024). Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052984"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tucci, M., Passarelli, A., Mannavola, F., Felici, C., Stucci, L.S., Cives, M., and Silvestris, F. (2019). Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01148"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): Potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Seidel, J.A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00086"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78174","DOI":"10.18632\/oncotarget.19836","article-title":"BRAF inhibitors: Resistance and the promise of combination treatments for melanoma","volume":"8","author":"Griffin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","first-page":"47","article-title":"Neoadjuvant therapy for melanoma: New and evolving concepts","volume":"20","author":"Erstad","year":"2022","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CMR.0000000000000832","article-title":"Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors","volume":"32","author":"Ismail","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_25","first-page":"217","article-title":"Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses","volume":"1785","author":"Guo","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11912-024-01611-9","article-title":"Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review","volume":"26","author":"Kalsi","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Slominski, R.M., Kim, T.K., Janjetovic, Z., Brozyna, A.A., Podgorska, E., Dixon, K.M., Mason, R.S., Tuckey, R.C., Sharma, R., and Crossman, D.K. (2024). Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling. Cancers, 16.","DOI":"10.3390\/cancers16122262"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","article-title":"Chemotherapy for Melanoma","volume":"167","author":"Wilson","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103304","DOI":"10.1016\/j.critrevonc.2021.103304","article-title":"Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma","volume":"161","author":"Zaleski","year":"2021","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in Cutaneous Melanoma: Is There Still a Role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40257-016-0174-8","article-title":"Combination Therapies for Melanoma: A New Standard of Care?","volume":"17","author":"Smalley","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hadash-Bengad, R., Hajaj, E., Klein, S., Merims, S., Frank, S., Eisenberg, G., Yakobson, A., Orevi, M., Caplan, N., and Peretz, T. (2020). Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00070"},{"key":"ref_33","first-page":"568","article-title":"[Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules]","volume":"64","author":"Tabaczar","year":"2010","journal-title":"Post\u0119py Hig. Med. Do\u015bwiadczalnej"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0959-8049(94)90456-1","article-title":"Docetaxel (Taxotere) in advanced malignant melanoma: A phase II study of the EORTC Early Clinical Trials Group","volume":"30A","author":"Aamdal","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.1995.13.12.2895","article-title":"Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy","volume":"13","author":"Bedikian","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_36","first-page":"63","article-title":"Docetaxel in the treatment of non-small cell lung carcinoma: An update and analysis","volume":"1","author":"Gubens","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Alsherbiny, M.A., Bhuyan, D.J., Low, M.N., Chang, D., and Li, C.G. (2021). Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810103"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"154591","DOI":"10.1016\/j.prp.2023.154591","article-title":"Angiogenesis and prostate cancer: MicroRNAs comes into view","volume":"248","author":"Gupta","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20622","DOI":"10.1038\/s41598-020-77674-y","article-title":"Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma","volume":"10","author":"Go","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Marzeda, P., Wroblewska-Luczka, P., Drozd, M., Florek-Luszczki, M., Zaluska-Ogryzek, K., and Luszczki, J.J. (2022). Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126752"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: New perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/09537104.2017.1378809","article-title":"Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload","volume":"30","author":"Harper","year":"2019","journal-title":"Platelets"},{"key":"ref_45","first-page":"672","article-title":"Beyond gold: The chemoenhancing mechanism and therapeutic potential of auranofin in melanoma","volume":"22","author":"Wang","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_46","first-page":"1218","article-title":"The Most Common Side Effects Experienced by Patients Were Receiving First Cycle of Chemotherapy","volume":"47","author":"Altun","year":"2018","journal-title":"Iran. J. Public Health"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/cncr.34718","article-title":"Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy","volume":"129","author":"Galus","year":"2023","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bachari, A., Piva, T.J., Salami, S.A., Jamshidi, N., and Mantri, N. (2020). Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176040"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2015.11.011","article-title":"Metastatic melanoma treatment: Combining old and new therapies","volume":"98","author":"Davey","year":"2016","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e15144","DOI":"10.1111\/exd.15144","article-title":"Melanoma and cannabinoids: A possible chance for cancer treatment","volume":"33","author":"Galeano","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1633","DOI":"10.1002\/wsbm.1633","article-title":"Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment","volume":"16","author":"Bachari","year":"2024","journal-title":"WIREs Mech. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bachari, A., Nassar, N., Telukutla, S., Zomer, R., Piva, T.J., and Mantri, N. (2024). Evaluating the Mechanism of Cell Death in Melanoma Induced by the Cannabis Extract PHEC-66. Cells, 13.","DOI":"10.3390\/cells13030268"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bachari, A., Nassar, N., Telukutla, S., Zomer, R., Dekiwadia, C., Piva, T.J., and Mantri, N. (2023). In Vitro Antiproliferative Effect of Cannabis Extract PHEC-66 on Melanoma Cell Lines. Cells, 12.","DOI":"10.3390\/cells12202450"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/med.20242","article-title":"Drugs that target dynamic microtubules: A new molecular perspective","volume":"31","author":"Stanton","year":"2011","journal-title":"Med. Res. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Buchtova, T., Lukac, D., Skrott, Z., Chroma, K., Bartek, J., and Mistrik, M. (2023). Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032885"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biocel.2015.05.016","article-title":"Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration","volume":"65","author":"Gamberi","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: Repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"ref_61","first-page":"32","article-title":"Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models","volume":"45","author":"Mirabelli","year":"1985","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0006-2952(86)90078-X","article-title":"Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions","volume":"35","author":"Snyder","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1038\/s41467-025-62634-9","article-title":"Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bukowska, B. (2024). Current and Potential Use of Biologically Active Compounds Derived from Cannabis sativa L. in the Treatment of Selected Diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252312738"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s43440-021-00308-1","article-title":"Cannabinoids and their derivatives in struggle against melanoma","volume":"73","author":"Marzeda","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.7150\/thno.39831","article-title":"Cooperation of endogenous and exogenous reactive oxygen species induced by zinc peroxide nanoparticles to enhance oxidative stress-based cancer therapy","volume":"9","author":"Lin","year":"2019","journal-title":"Theranostics"},{"key":"ref_67","first-page":"137289","article-title":"Oxidative stress and lipid peroxidation products in cancer progression and therapy","volume":"2012","author":"Barrera","year":"2012","journal-title":"ISRN Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1039\/C6CS00271D","article-title":"Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy","volume":"45","author":"Zhou","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic Drug-Drug Interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Boyd, K.N., and Mailman, R.B. (2012). Dopamine receptor signaling and current and future antipsychotic drugs. The Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-642-25761-2_3"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.2174\/138161209789649475","article-title":"Use of cell lines in the investigation of pharmacogenetic loci","volume":"15","author":"Zhang","year":"2009","journal-title":"Curr. Pharm. Des."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:11:51Z","timestamp":1776240711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041794"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041794","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}